Blueprint Medicines Corp (BPMC)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Kathryn Haviland
Employees:
640
45 SIDNEY STREET, CAMBRIDGE, MA, 02139
617-374-7580
Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|